The acquisition will grant Roche full ownership over a pipeline of allogeneic CAR-T therapy candidates, including two ...
MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.
Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.
California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...
We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t ...
The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the ...
The global contract development and manufacturing organization ​ (CDMO), Samsung Biologics, announced this week that it has ...
The global contract development and manufacturing organization (CDMO), Samsung Biologics, announced this week that it has entered into a collaboration with an undisclosed European pharmaceutical ...
From developing treatments for Ebola to mastering karate with her daughters, Dr. Helen Harrington’s journey is one of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback